Dare Bioscience (DARE) Debt/Assets Ratio: History & Chart

Dare Bioscience, Inc.(DARE)

Biotechnology · San Diego, CA

$0.86+0.02 (+2.02%)

Delayed quote: Oct 6, 2026, 9:40 AM EDT

About Dare Bioscience, Inc.

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

San Diego, CA

23 employees

darebioscience.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Sabrina Martucci Johnson

View full financials

DARE Debt to Assets Ratio Metrics

DEBT TO ASSETS RATIO

30.24%

DEBT TO ASSETS RATIO AVG TTM

15.42%

DEBT TO ASSETS RATIO AVG 3Y

6.49%

DEBT TO ASSETS RATIO AVG 5Y

4.32%

DEBT TO ASSETS RATIO AVG 10Y

5.10%

DEBT TO ASSETS RATIO AVG 15Y

N/A

DEBT TO ASSETS RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

+96.03%

CURRENT VS 3Y AVG

+365.80%

CURRENT VS 5Y AVG

+599.90%

CURRENT VS 10Y AVG

+492.66%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.11%

median of 532 covered companies

CURRENT VS SECTOR MEDIAN

+28695.34%

vs the sector median at left

NAME	MARKET CAP	DEBT TO ASSETS RATIO	TTM	3Y	5Y
Dare Bioscience, Inc. (DARE)	$12.88M	30.24%	15.42%	6.49%	4.32%
Cytosorbents Corporation (CTSO)vs ›	$12.95M	0.69%	N/A	N/A	N/A
IRIDEX Corporation (IRIX)vs ›	$12.70M	0.15%	N/A	N/A	N/A
Lantern Pharma Inc. (LTRN)vs ›	$12.22M	0.00%	N/A	N/A	N/A
IN8bio, Inc. (INAB)vs ›	$13.71M	0.10%	N/A	N/A	N/A
Vyome Holdings, Inc. (HIND)vs ›	$13.76M	0.00%	N/A	N/A	N/A
Cellectar Biosciences, Inc. (CLRB)vs ›	$13.78M	0.04%	N/A	N/A	N/A
Adial Pharmaceuticals, Inc. (ADIL)vs ›	$11.65M	0.00%	N/A	N/A	N/A
Lisata Therapeutics, Inc. (LSTA)vs ›	$11.38M	0.00%	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$14.44M	0.05%	N/A	N/A	N/A

NAME

MARKET CAP

DEBT TO ASSETS RATIO

TTM

Dare Bioscience, Inc. (DARE)

$12.88M

30.24%

15.42%

6.49%

4.32%

Cytosorbents Corporation (CTSO)vs ›

$12.95M

0.69%

N/A

IRIDEX Corporation (IRIX)vs ›

$12.70M

0.15%

N/A

Lantern Pharma Inc. (LTRN)vs ›

$12.22M

0.00%

N/A

IN8bio, Inc. (INAB)vs ›

$13.71M

0.10%

N/A

Vyome Holdings, Inc. (HIND)vs ›

$13.76M

0.00%

N/A

Cellectar Biosciences, Inc. (CLRB)vs ›

$13.78M

0.04%

N/A

Adial Pharmaceuticals, Inc. (ADIL)vs ›

$11.65M

0.00%

N/A

Lisata Therapeutics, Inc. (LSTA)vs ›

$11.38M

0.00%

N/A

Citius Pharmaceuticals, Inc. (CTXR)vs ›

$14.44M

0.05%

N/A

Debt to Assets Ratio FAQ

What is the debt to assets ratio for Dare Bioscience, Inc. (DARE)?

The debt to assets ratio for DARE stock is 30.24%.

Is Dare Bioscience, Inc.'s debt to assets ratio high or low?

The debt to assets ratio of 30.24% is 600% above its 5-year average of 4.32%, around the middle of its 5-year range (0.48%–44.65%).

What is the TTM average debt to assets ratio for Dare Bioscience, Inc. (DARE)?

The TTM average debt to assets ratio for DARE stock is 15.42%.

What is the 3Y average debt to assets ratio for Dare Bioscience, Inc. (DARE)?

The 3Y average debt to assets ratio for DARE stock is 6.49%.

What is the 5Y average debt to assets ratio for Dare Bioscience, Inc. (DARE)?

The 5Y average debt to assets ratio for DARE stock is 4.32%.

What is the 10Y average debt to assets ratio for Dare Bioscience, Inc. (DARE)?

The 10Y average debt to assets ratio for DARE stock is 5.10%.

DATE	DEBT TO ASSETS RATIO
2026-06-30	30.24%
2026-03-31	5.80%
2025-12-31	8.18%
2025-09-30	9.54%
2025-06-30	23.37%
2025-03-31	44.65%
2024-12-31	5.90%
2024-09-30	7.77%
2024-06-30	6.46%
2024-03-31	12.62%
2023-12-31	6.60%
2023-09-30	0.78%
2023-06-30	1.27%
2023-03-31	1.29%
2022-12-31	1.12%
2022-09-30	1.16%
2022-06-30	2.23%
2022-03-31	2.46%
2021-12-31	0.48%
2021-09-30	0.79%
2021-06-30	3.32%
2021-03-31	5.67%
2020-12-31	10.02%
2020-09-30	11.22%
2020-06-30	11.20%
2020-03-31	6.74%
2019-12-31	10.75%
2019-09-30	7.10%
2019-06-30	1.60%
2019-03-31	2.77%
2018-12-31	0.00%
2018-09-30	0.00%
2018-06-30	0.00%
2018-03-31	0.00%
2017-12-31	0.00%
2017-09-30	0.00%
2017-06-30	10.46%
2017-03-31	5.00%
2016-12-31	34.02%
2016-09-30	36.73%
2016-06-30	33.40%
2016-03-31	29.38%
2015-12-31	25.98%
2015-09-30	18.17%
2015-06-30	16.44%
2015-03-31	24.27%
2014-12-31	5.85%
2014-09-30	6.55%
2014-06-30	7.19%
2014-03-31	192.54%
2013-12-31	91.67%

DATE

DEBT TO ASSETS RATIO

2026-06-30

30.24%

2026-03-31

5.80%

2025-12-31

8.18%

2025-09-30

9.54%

2025-06-30

23.37%

2025-03-31

44.65%

2024-12-31

5.90%

2024-09-30

7.77%

2024-06-30

6.46%

2024-03-31

12.62%

2023-12-31

6.60%

2023-09-30

0.78%

2023-06-30

1.27%

2023-03-31

1.29%

2022-12-31

1.12%

2022-09-30

1.16%

2022-06-30

2.23%

2022-03-31

2.46%

2021-12-31

0.48%

2021-09-30

0.79%

2021-06-30

3.32%

2021-03-31

5.67%

2020-12-31

10.02%

2020-09-30

11.22%

2020-06-30

11.20%

2020-03-31

6.74%

2019-12-31

10.75%

2019-09-30

7.10%

2019-06-30

1.60%

2019-03-31

2.77%

2018-12-31

0.00%

2018-09-30

0.00%

2018-06-30

0.00%

2018-03-31

0.00%

2017-12-31

0.00%

2017-09-30

0.00%

2017-06-30

10.46%

2017-03-31

5.00%

2016-12-31

34.02%

2016-09-30

36.73%

2016-06-30

33.40%

2016-03-31

29.38%

2015-12-31

25.98%

2015-09-30

18.17%

2015-06-30

16.44%

2015-03-31

24.27%

2014-12-31

5.85%

2014-09-30

6.55%

2014-06-30

7.19%

2014-03-31

192.54%

2013-12-31

91.67%

Debt to Assets Ratio: 30.24%

DARE Debt to Assets Ratio

DARE Average Debt to Assets Ratio Chart

DARE Current vs Average Debt to Assets Ratio Chart

DARE Debt to Assets Ratio Metrics

DARE Competitors' Debt to Assets Ratio

Leverage Ratios Comparison

Debt to Assets Ratio Formula & Definition

Debt to Assets Ratio FAQ

DARE Debt to Assets Ratio History

Related Metrics